Table 3. Univariate analysis of the... | American Society of Hematology

Table 3.

Univariate analysis of the ASXL1 rs4911231 and BIM rs686952 variants in nilotinib-treated patients

Factor	No. of patients	12-mo MMR		24-mo MR⁴		24-mo MR^4.5		24-mo FFS
Factor	No. of patients	%	P	%	P	%	P	%	P
ASXL1 rs4911231 genotype			.28		.048		.31		.537
Good risk	23	78		66		32		86
Poor risk	55	67		42		20		92
BIM rs686952 genotype			.52		.77		.17		.877
Good risk	33	70		45		31		91
Poor risk	43	70		50		16		88

Factor	No. of patients	12-mo MMR		24-mo MR⁴		24-mo MR^4.5		24-mo FFS
Factor	No. of patients	%	P	%	P	%	P	%	P
ASXL1 rs4911231 genotype			.28		.048		.31		.537
Good risk	23	78		66		32		86
Poor risk	55	67		42		20		92
BIM rs686952 genotype			.52		.77		.17		.877
Good risk	33	70		45		31		91
Poor risk	43	70		50		16		88